Clinical trials
High-Risk Cancer clinical trials
Below are recruiting high-risk cancer clinical trials, each written for real people, not researchers. We’re tracking 392 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06348264RecruitingPhase 2
Rezvilutamide with hormone therapy for high-risk salivary duct cancer
This trial tests a new drug, Rezvilutamide, combined with standard hormone therapy for people with a rare and aggressive type of salivary gland cancer that has a high risk of coming back. The treatment aims to reduce the chance of cancer returning after surgery.
Beijing, Beijing MunicipalityAges 18 years+ - NCT07317700RecruitingPhase 3
Testing a new treatment for intermediate or high-risk myelofibrosis
This trial tests an oral medication (Flonoltinib Maleate) for people with intermediate or high-risk myelofibrosis, including primary myelofibrosis or those that developed after other blood disorders. It aims to see if the drug can safely reduce spleen size and improve symptoms.
Chengdu, SichuanAges 18–80 - NCT07552805Recruiting
Home monitoring device after major digestive surgery
This study tests a wearable patch called Multisense that monitors your health at home after major gastrointestinal surgery. It's designed to catch problems early so you can stay safe and avoid returning to the hospital.
Nice, Alpes-MaritimesAges 18 years+ - NCT05768464RecruitingPhase 2
Surgery aftercare for non-clear kidney cancer at high risk
This Phase 2 trial studies an after-surgery treatment for people with non-clear types of kidney cancer who are at high risk of coming back. It aims to lower the chance of recurrence by giving extra therapy after your tumor is completely removed.
Nanjing, JiangsuAges 18–75 - NCT07463287Recruiting
Fatty liver and colorectal polyp risk study
This study looks at whether certain gene activity in people with fatty liver disease can predict the risk of developing colorectal polyps. It may help doctors find high-risk patients earlier.
Shanghai, Shanghai MunicipalityAges 18–70 - NCT07415707Recruiting
Reducing alcohol and taking probiotics for brain health in older adults
This study tests whether cutting back on alcohol and taking probiotics can improve memory and thinking in older adults who are heavy drinkers. If you are interested in drinking less, you may be able to join.
Miami, FloridaAges 65–84 - NCT05912816RecruitingPhase 2
Kidney-protecting treatment for high-risk upper urinary tract cancer
This trial tests whether combining DV with tislelizumab can help protect kidney function in people with high-risk cancer in the upper urinary tract (the renal pelvis or ureter). It may help preserve the kidneys while treating the cancer more effectively.
Shanghai, Shanghai MunicipalityAges 18–90 - NCT06610773RecruitingPhase 1/Phase 2
Stem cell treatment for high-risk HPV infection
This trial tests whether umbilical cord stem cells can help clear a persistent high-risk HPV infection. It is for women aged 25 to 60 who have had HPV for a while and have not been treated with other HPV drugs recently.
Shanghai, Shanghai MunicipalityAges 25–60 - NCT06287944RecruitingPhase 1
Targeted radiation and chemo before donor stem cell transplant
This trial tests a new approach: giving a targeted radioactive antibody (attached to a drug that finds CD38 on cancer cells) along with low-dose chemotherapy and targeted radiation to the bone marrow before a donor stem cell transplant. The goal is to prepare the body for the transplant while killing remaining cancer cells more precisely.
Duarte, CaliforniaAges 18–70 - NCT03689595Enrolling by invitation
PROMISE study: Predicting myeloma risk in high-risk groups
This study uses a blood test to find early signs of myeloma in people at higher risk, such as those with a family history or African ancestry. It aims to predict who might develop myeloma before symptoms appear.
Boston, MassachusettsAges 30 years+ - NCT06528496RecruitingPhase 2
Less chemo plus antibody therapy for high-risk neuroblastoma in children
This study tests whether giving fewer chemotherapy drugs along with other targeted therapies (monoclonal antibodies) works well for children with high-risk neuroblastoma. It aims to reduce side effects while still treating the cancer effectively.
New York, New YorkAges 1.5 years–19 years - NCT05890716Recruiting
AI analyzes your ECG to help in high-risk heart rhythm cases
This trial uses an AI program to review ECG heart-tracing data collected from short-term monitoring devices. It aims to see whether the AI can better detect concerning heart rhythm patterns in people who are high risk for heart rhythm or heart problems.
Groningen, Provincie GroningenAges 4 years+ - NCT03959085RecruitingPhase 3
Inotuzumab plus chemotherapy for high-risk childhood leukemia
This Phase 3 trial tests whether adding inotuzumab to standard post-induction chemotherapy improves outcomes for children and young teens with high-risk B-ALL, mixed phenotype acute leukemia (MPAL), or certain high-risk B-LLy. It may help by targeting leukemia cells more directly, but participation depends on specific age, lab results, and medical history rules.
Birmingham, AlabamaAges 12 months–25 years - NCT07372131Recruiting
Shorter antibiotics for high-risk fever with low white blood cells
This study looks at how long antibiotics should be given to cancer patients with fever and very low white blood cell counts after finding a certain type of bacteria (Gram-negative) in their blood. The goal is to find the best treatment duration to help patients recover without complications.
Rozzano, MilanAges 18 years+ - NCT03113643RecruitingPhase 1
SL-401 with standard drugs for hard-to-treat blood cancers
This Phase 1 study tests SL-401, given with azacitidine and sometimes venetoclax, to treat acute myeloid leukemia (AML), high-risk myelodysplastic syndrome (MDS), or blastic plasmacytoid dendritic cell neoplasm (BPDCN). It aims to find a safe dose and see whether the combination can improve blood cancer control.
Duarte, CaliforniaAges 18 years+ - NCT03128034RecruitingPhase 1/Phase 2
Astatine-211 treatment before stem cell transplant for high-risk blood cancers
This trial tests a targeted radiation drug (Astatine-211) given before a donor stem cell transplant for people with high-risk leukemia or certain bone-marrow cancers. The goal is to better control the cancer before the transplant.
Seattle, WashingtonAges 18–75 - NCT03670966RecruitingPhase 1/Phase 2
Targeted iodine therapy, then donor transplant for hard leukemias
This trial tests an antibody-linked radioactive iodine treatment, followed by a donor stem cell transplant, for people with relapsed or refractory high-risk acute leukemia or certain MDS. It may help patients by targeting leukemia cells and then using a new immune system to control the disease.
Seattle, WashingtonAges 18–75 - NCT03937635RecruitingPhase 3
Lenalidomide and dexamethasone, with or without daratumumab
This phase 3 trial studies whether lenalidomide plus dexamethasone can prevent or delay progression of “high-risk smoldering” multiple myeloma, and whether adding daratumumab improves outcomes. It’s meant for people who are not yet showing symptoms, but whose lab and scan results suggest higher risk.
Birmingham, AlabamaAges 18 years+ - NCT05371808Recruiting
Early vs delayed treatment for high-risk CLL: cost study
This study compares early treatment versus delaying treatment in newly diagnosed people with high-risk CLL/SLL who feel well. It mainly looks at the overall “costs and value” of each approach and asks patients to complete short health and quality-of-life questionnaires.
Vancouver, British ColumbiaAges 18 years+ - NCT04025450RecruitingPhase 1/Phase 2
Tested stronger combo for high-risk myeloma patients
This early-phase study compares two drug combinations—chidamide plus VRD versus VRD alone—to see which works better for primary high-risk multiple myeloma. The goal is to improve response while closely monitoring side effects and heart/lung safety.
Suzhou, JiangsuAges 18–80 - NCT04140487RecruitingPhase 1/Phase 2
Study drugs for certain FLT3-mutated blood cancers that have returned
This trial tests a combination of three medicines—azacitidine, venetoclax, and gilteritinib—in people with specific gene changes (FLT3 mutations) in leukemia and related bone marrow diseases that have come back or are hard to treat. The goal is to see if this drug combination can control the disease and improve outcomes.
Houston, TexasAges 18 years+ - NCT04243785RecruitingPhase 1
Testing BTX-A51 for hard-to-treat AML or high-risk MDS
This Phase 1 study tests BTX-A51 in adults with relapsed or refractory acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome (MDS). It’s designed to see if the treatment can be given safely and to learn how it works in people whose standard treatments have not helped or are no longer an option.
Duarte, CaliforniaAges 18 years+ - NCT04493164RecruitingPhase 2
CPX-351 plus ivosidenib for IDH1-mutated leukemia or high-risk MDS
This trial tests CPX-351 together with ivosidenib in people with IDH1-mutated acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome (MDS). It aims to improve disease control, especially in tumors with a specific genetic change called IDH1.
Houston, TexasAges 18 years+ - NCT04708054RecruitingPhase 2/Phase 3
Venetoclax with busulfan chemo for high-risk AML or MDS
This study tests whether adding venetoclax to a specific busulfan-based chemotherapy plan improves outcomes for people with high-risk AML or MDS. It mainly targets patients whose leukemia/marrow disease still has high-risk features or measurable disease after initial treatment.
Houston, TexasAges 18–70
Hear when a new High-Risk Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for high-risk cancer?
- Yes. Clin2 currently lists 392 recruiting high-risk cancer studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a high-risk cancer trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a high-risk cancer trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.